Board summary
Key figures
59,563
Registered population
59.4% aged 18–64
22.3%
Aged 65+
ICB 20.0% · England 17.9%
1.9%
Ethnic minority (non-White)
0.8% Asian
36.5%
In IMD quintile 1
ICB 30.6% · England 21.0%
~24,652
Core20 residents (est.)
Resident basis; registered basis ~22,352 · see page 3
10,003
Hypertension register
+3.43% in 3 yrs · England +5.60%
699
SMI register
31.7% of Westmorland and Furness (LAD)'s
1,713
COPD register
Reviews +0.33% in 3 yrs
Forecast to 2030
11,175
Hypertension patients, 2030
+1,172 on today
77.2%
QRISK ≥20% on statins, 2030
+4.59pp over 3 yrs
4.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Unreviewed asthma patients alongside high youth prescribing.
With 67.4% of 4,739 asthma patients reviewed and 2,512 items per 1,000 aged 5-19 (England 1,488), 1,546 lack reviews, which may reflect recall gaps.
Frail diabetes and 80+ blood pressure lag.
Frail diabetes HbA1c control is 78.3% (England 81.9%) and 80+ BP control is 79.7% (-2.4% vs England +2.2%), which may reflect review access.
Strong statin and lipid-lowering therapy reach.
Statin treatment in diabetes without CVD is 78.1% (+6.7% vs England +2.1%) and QRISK ≥20% lipid therapy is 67.0% (England 63.6%).
Population, age and ethnicity
Patients aged 65 and over make up 22.3% of registrations, exceeding England's 17.9%
Barrow Together PCN serves 59,563 registered patients across member practices. Patients aged 65 and over comprise 22.3% (13,284 patients) of the list, below Westmorland and Furness LAD (25.9%), but above NHS Lancashire and South Cumbria ICB (20.0%) and England (17.9%). Adults aged 18–64 make up 59.4% (35,370) and those aged 0–17 represent 18.3% (10,909). Census resident data shows 98.2% White and 1.9% ethnic minority groups; area Census shares do not establish registered-patient ethnicity. An older age structure compared with England is consistent with higher demand for chronic disease management.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Westmorland and Furness (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Westmorland and Furness LA) | 1,591 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Westmorland and Furness LA) | 736 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Westmorland and Furness LA) | 10.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 36.5% of the PCN, with an 82.2 pp practice range
The PCN has 36.5% of registered patients in the Core20 most deprived quintile, above Westmorland and Furness LAD (9.2%), NHS Lancashire and South Cumbria ICB (30.6%) and England (21.0%). Deprivation spans an 82.2 pp range: The Family Practice has the highest concentration at 82.2% (2,318 estimated Core20 patients), while Duke Street Surgery has the highest volume with 4,699 estimated Core20 patients. Modelled weighted practice share (37.5%) differs from the PCN rate. Clinical outreach should prioritise high-concentration practices while administrative capacity addresses high-volume lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
699
SMI register
1.16% recorded prevalence
422
Learning disability register
0.70% recorded prevalence
11
Care homes, 513 beds
In the PCN catchment
Severe mental illness prevalence is 1.2% (699 patients), against 0.9% in Westmorland and Furness LAD, 1.2% in the ICB and 1.0% in England. Learning disability prevalence is 0.7% (422 patients; comparators all 0.6%). Catchment care homes total 11 with 513 beds, though capacity does not confirm GP registrations. The SMI register is above the England rate, so physical-health checks for this group are the larger workload to protect.
Severe mental illness: physical health checks
On the SMI register (1.2% prevalence), 83.4% had a BP check (matching England 83.4%), while BMI recording was 79.8% (England 82.1%) and alcohol recording reached 77.7% (England 81.8%). Trailing physical check elements may leave cardiometabolic risks unmonitored.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,003
Hypertension register
+3.43%
Register growth, 3 yrs
Westmorland and Furness (LAD) +6.93% · England +5.60%
+1.92pp
BP control, under 80
≤140/90 · −1.93pp aged 80+
+1,172
More patients by 2030
Forecast 11,175 (17.72%)
Hypertension case-finding and control
Hypertension prevalence is 16.6% (10,003 patients), above England (15.2%) but below Westmorland and Furness LAD (18.2%) and the ICB (17.2%). While blood pressure control for patients under 80 is 68.2% (England 67.8%), control at age 80+ is 79.7%, trailing England (81.2%), the LAD (81.5%) and the ICB (81.8%), having fallen 2.4% over 2023 to 2025 (England +2.2%). Recent blood pressure recording sits at 88.6% (England 90.0%). Older hypertensive patients trail national control benchmarks following a three-year decline, so prioritising dedicated blood pressure reviews for patients aged 80 and over is the key clinical opportunity.
Lipids and statins
Lipid-lowering therapy reaches 67.0% of patients with QRISK ≥ 20%, exceeding England (63.6%), Westmorland and Furness LAD (59.6%) and the ICB (61.4%). Statin coverage in diabetes without CVD is 78.1% (England 73.2%). With primary prevention lipid treatment exceeding all comparators, the PCN should sustain current initiation pathways across high-risk groups.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 139,764 | £1.90 | £1.64 | £1.86 | £265,552 |
| Cardiovascular (all), 2025 | 195,236 | £3.20 | £3.38 | £3.33 | £624,755 |
In 2026, lipid-modifying prescribing cost £1.90 per item across 139,764 items (£265,552 spend), above England (£1.86), Westmorland and Furness LAD (£1.68) and the ICB (£1.64). The PCN spent £36,339 more than at the ICB unit cost and £5,591 more than England. Higher unit spend than regional benchmarks suggests an opportunity to review lipid-modifying formulary choices across member practices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.25%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.46%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.3% (4,739 patients; England 6.6%), and asthma management prescribing at ages 5-19 reaches 2,512 items per 1,000 (England 1,488; ICB 1,828). However, annual asthma review reach is 67.4% (LAD 70.4%), growing just +0.2% over three years (England +4.4%), leaving 1,546 patients unreviewed. Second-hand smoke recording for ages 6-19 is 75.7% (England 78.8%). Meanwhile, COPD prevalence is 2.8% (1,713 patients; England 1.9%), but fell 3.4% over three years (England +2.6%). High youth prescribing alongside review shortfalls could indicate uncontrolled asthma requiring proactive paediatric review.
Cancer register and children's immunisation
The cancer register records 2,628 patients (4.3% prevalence; England 3.8%, LAD 5.3%). In childhood immunisation, age-5 MMR1 achieves 96.6% (exceeding the 95.0% target), but MMR2 is 94.1% (a 2.5 pp difference), and the 4-in-1 pre-school booster reaches 90.7% (4.3 pp below the 95.0% target). While exceeding England (80.9%), lower pre-school booster coverage indicates a potential protection gap.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, NHS Lancashire and South Cumbria ICB diagnosed 52.4% of staged cancers at stage 1 or 2 (4,642 of 8,863 known-stage cases; 74.6% known-stage share), 22.6 pp below the 75.0% national ambition and trailing England (55.3%). Early-stage share fell 1.2 pp from 53.6% in 2013 (about 2,010 extra cases needed). In Barrow Together PCN, cervical screening at ages 25-49 is 66.5% (Westmorland and Furness LAD 72.2%), falling 4.9% over 2023 to 2025 (England -1.0%). The Family Practice recorded 54.2%, Norwood Medical Centre recorded 57.5%, and Risedale Surgery recorded 63.1%. Stage data reflects ICB geography, not PCN delivery. Lower cervical screening may delay early detection; practice recall audits would test.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At University Hospitals of Morecambe Bay NHS Foundation Trust, the 62-day cancer referral to treatment standard was 12.6 pp below the 85.0% standard. The trust was 3.4 pp above the 75.0% 28-day faster diagnosis standard and 0.8 pp below the 96.0% 31-day combined treatment standard. Across NHS Lancashire and South Cumbria Integrated Care Board, 62-day referral to treatment was 11.4 pp below the 85.0% standard. Barrow Together PCN cancer prevalence is 4.3% (2,628 patients); acute waits describe system context, not PCN delivery. Prolonged acute treatment waits may require robust PCN safety-netting while patients await definitive cancer therapy.
| Pathways within standard (%) | of Morecambe Bay | Blackpool | Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 71.38 | 82.90 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 97.96 | 89.43 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 67.48 | 75.04 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | Blackpool | Lancashire | England |
|---|---|---|---|---|
| MRI | 4.04 | 21.80 | 2.41 | 21.40 |
| CT | 13.76 | 16.49 | 14.97 | 9.92 |
| Echocardiography | 10.55 | 7.57 | 13.85 | 28.48 |
| Colonoscopy | 0.60 | 13.08 | 0.00 | 30.83 |
| Gastroscopy | 1.45 | 12.47 | 0.00 | 29.02 |
| All 15 DM01 tests | 10.44 | 26.54 | 26.65 | 23.14 |
| Community services activity | Westmorland and Furness residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 53,485 | 193,720 |
| Referrals | 6,470 | 29,855 |
| Patients with a contact | 13,445 | 65,335 |
Community services (residents of Westmorland and Furness), Jun 2026 (provisional). In the provisional Community Services Dataset for Jun 2026, Westmorland and Furness residents recorded 53,485 community contacts, of which 36,330 (67.9%) were for adults aged 65 and over. These figures describe borough-wide activity rather than PCN performance. Substantial community use among older residents indicates an opportunity to coordinate primary care reviews with borough community nursing teams.
Practice variation and patient experience
Vaccination and immunisation achievement varies across practices by 51.7 pp
Across England, overall QOF achievement was 92.5% in 2025/26. Overall QOF achievement was 86.3% at Atkinson Health Centre, whereas it was 97.5% at Duke Street Surgery. Vaccination and immunisation-domain achievement varies by 51.7 pp between captured practices, recorded at 40.9% for The Family Practice and 92.6% for Risedale Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Abbey Road Surgery | 126 | 16.4 | 89.2% | 77.0% | 87.9% |
| Atkinson | 110 | 48.5 | 73.1% | 82.4% | 86.0% |
| Burnett Edgar | 129 | 0.0 | 75.8% | 70.6% | 84.3% |
| Duke Street | 140 | 41.3 | 64.3% | 66.6% | 76.8% |
| Bridgegate | 108 | 39.2 | 59.2% | 63.8% | 72.6% |
| Norwood | 107 | 35.4 | 40.0% | 69.6% | 66.2% |
| The | 96 | 82.2 | 67.0% | 40.4% | 61.9% |
| Risedale Surgery | 106 | 46.3 | 54.1% | 73.7% | 59.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Between 2023 and 2025, 21 of 25 measures trailed England's three-year change
Between 2023 and 2025, 21 of 25 compared measures trailed England's 3-year change. The widest shortfalls were in heart failure reviews (-0.1% versus England +8.7%), dementia registers (-0.5% versus England +6.0%), psychosis alcohol recording (-1.1 pp versus England +5.4 pp), COPD registers (-3.4% versus England +2.6%), and learning disability (-0.5% versus England +5.4%). Conversely, non-frail diabetes HbA1c control beat England (+9.2% versus +4.4%), alongside diabetes statin therapy without CVD (+6.7% versus +2.1%) and with CVD (+4.0% versus +1.0%). Trailing trends may reflect recall or coding lag, which local practice audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
Alcohol record (psychosis)
COPD register
Learning disability register
Diabetes HbA1c control
Diabetes statin (no CVD)
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Westmorland and Furness (LAD) | Asset | PCN | Westmorland and Furness (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (513 beds) | n/a | Schools (catchment) | 64 | n/a |
| Children's centres | 4 | 12 | Places of worship | 33 | 316 |
| Libraries | 2 | 14 | Food banks (VCS) | n/a | 2 |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 3 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 14 | 82 |
| Primary academies | 10 | 27 | Special schools | n/a | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Asthma review reach is 67.4% (+0.2% over 2023 to 2025 vs England +4.4%, LAD 70.4%), leaving 1,546 of 4,739 patients unreviewed alongside 2,512 items per 1,000 aged 5-19 (England 1,488). For discussion: run structured asthma recall using a shared template, offering after-school slots and reviewing inhaler prescribing. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Frailty diabetes and 80+ hypertension recall
Frail diabetes HbA1c <=75 mmol/mol in 2024/25 is 78.3% (836 of 1,068; England 81.9%); BP <=150/90 mmHg at age 80+ is 79.7% (England 81.2%, LAD 81.5%), down 2.4% over 2023 to 2025. For discussion: run pharmacist-led recall and home or care-home medication reviews for frail diabetic and 80+ hypertensive patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school booster and MMR2 catch-up recall
In Q1 2025/26 (cohort 120), age-5 4-in-1 coverage is 90.7% (4.3 pp below the 95.0% target) and MMR2 is 94.1% (2.5 pp below MMR1 at 96.6%), with a 51.7 pp QOF vaccination range. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population review coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Mental health physical check outreach (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older hypertensive review audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Frailty diabetes and 80+ hypertension recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school booster and MMR2 catch-up recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
